Develops and commercializes non-opioid pain management solutions. Offers EXPAREL, a long-lasting, local analgesia for post-surgical pain. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $216.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 141.8× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 89% of them.
Analysts' average target sits 13% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price looks reasonable next to what the company earns.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
The company’s market value is 142 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, PCRX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: PCRX is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.